PEGylated nanoproducts are a type of nanomedicine that consists of a drug molecule that is conjugated to a PEG molecule. The PEG molecule has several properties that make it well-suited for drug delivery such as its biodegradability and safe to consume, aqueous-solubility (easy uptake by the body), protecting drug from degradation with good longevity, and facilitating the drug to be administered to the target tissues for an extended period. PEGylated nanoproducts are an exciting new class of pharmaceutical drugs for several disorders like cancer, cardiovascular disease, and infectious diseases because of these characteristics. However, several regulatory and patent issues need to be addressed before these products can be widely adopted. The FDA has not yet developed specific guidelines for the clinical development of PEGylated nanoproducts. This means that companies developing these products need to work closely with the FDA to ensure that their products meet all of the necessary safety and efficacy requirements. Several patent issues need to be considered. The patent landscape for PEGylated nanoproducts is complex and there is a risk of patent infringement. Companies developing these products need to carefully assess the patent landscape before they begin clinical development. Despite the challenges, the potential benefits of PEGylated nanoproducts are significant. These products have the potential to enhance the efficacy and safety of drugs and they could revolutionize the treatment of a variety of diseases.